Project 170340
Elucidation of novel mechanisms of glucagon action
Elucidation of novel mechanisms of glucagon action
Project Information
| Study Type: | Trial Randomized_Controlled_Trial |
| Therapeutic Area: | Geriatrics |
| Research Theme: | Biomedical |
| Disease Area: | advance care planning and decisional capacity |
| Data Type: | Canadian |
Institution & Funding
| Principal Investigator(s): | Drucker, Daniel J |
| Institution: | Lunenfeld-Tanenbaum Research Institute (Toronto) |
| CIHR Institute: | Nutrition, Metabolism and Diabetes |
| Program: | |
| Peer Review Committee: | Metabolism |
| Competition Year: | 2008 |
| Term: | 5 yrs 0 mth |
Abstract Summary
Glucagon is a hormone secreted from the pancreas that together with insulin, controls levels of blood sugar through actions on the liver. Excess glucagon action in diabetic subjects underlies the inappropriate increase in blood glucose observed in diabetic subjects-hencing reducing glucagon action is a major goal for development of new agents to treat type 2 diabetes. The proposed studies analyze the consequences of attenuating glucagon action in mice with genetic disruption of the glucagon receptor. The Results of these studies are expected to extend our knowledge about how glucagon works, and to inform us about the likely safety and efficacy of new drugs used to block glucagon action for the treatment of diabetes.
Research Characteristics
This project includes the following research characteristics:
Study Justification
"evaluate the effectiveness of advance planning intervention for healthcare and research decisions among older adults"
Novelty Statement
"first study to assess efficacy of multimodal advance planning intervention for both healthcare and research decisions"
Methodology Innovation
combined healthcare and research advance planning intervention